Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bacillus coagulans + chitosan is a synbiotic formulation combining the spore-forming probiotic bacterium *Bacillus coagulans* with the prebiotic polymer chitosan (or its derivative, chitooligosaccharide). This combination is designed to act synergistically to restore gut microbiota homeostasis, enhance intestinal epithelial barrier integrity, and modulate immune responses. In preclinical models of ulcerative colitis, the synbiotic formulation has demonstrated therapeutic potential by preserving crypt architecture, maintaining goblet cell density, reducing pro-inflammatory cytokines (such as IL-6 and IL-8), and promoting the recovery of short-chain fatty acids (SCFAs) and tight junction proteins.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Bacillus coagulans + chitosan.